Metabolomic Diagnostics

Metabolomic Diagnostics (MetDx) is an early stage diagnostic company based in Cork, Ireland. We were formed in 2012 with a mission to develop novel screening tests for pregnancy complications.

Pre-eclampsia (PE) affects up to 8% of all pregnancies. Unfortunately, the disease is complex and remains hidden in early pregnancy. When clinical symptoms do eventually appear (usually after 6 months), PE can have serious health implications: the condition is responsible for the deaths of more than 70,000 mothers and 500,000 babies globally each year and for the millions of survivors, many will go on to have lifelong health complications. Preterm PE is when the disease occurs before week 37 and is responsible for most of these bad outcomes. The highest risk group is first time pregnancies where no prior history exists. The good news is that the condition can be treated with aspirin if taken by week 16 of gestation. Being able to predict, early in pregnancy, those women who are at high risk of developing Preterm PE later in pregnancy is the unmet clinical need, as knowing early to support clinical intervention would save the lives of mums and thier babies. 

Our first product PrePsia™, is a blood test (biomarker mass spectrometry-based assay) that when taken early can screen for Preterm PE in first time pregnancies supporting clinical intervention that can dramatically improve pregnancy outcomes.

PrePsia has the potential to form part of prenatal screening programs globally.